NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer

PURPOSE: The primary aim of NSABP FB-7 was to determine the pathologic complete response (pCR) rate in locally advanced HER2-positive (HER2(+)) breast cancer patients treated with neoadjuvant trastuzumab or neratinib or the combination and weekly paclitaxel followed by standard doxorubicin plus cycl...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Samuel A., Robidoux, André, Abraham, Jame, Pérez-Garcia, José Manuel, La Verde, Nicla, Orcutt, James M., Cazzaniga, Marina E., Piette, Fanny, Antolín, Silvia, Aguirre, Elena, Cortes, Javier, Llombart-Cussac, Antonio, Di Cosimo, Serena, Kim, Rim S., Feng, Huichen, Lipchik, Corey, Lucas, Peter C., Srinivasan, Ashok, Wang, Ying, Song, Nan, Gavin, Patrick G., Balousek, April D., Paik, Soonmyung, Allegra, Carmen J., Wolmark, Norman, Pogue-Geile, Katherine L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892191/
https://www.ncbi.nlm.nih.gov/pubmed/31796073
http://dx.doi.org/10.1186/s13058-019-1196-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892191/
https://www.ncbi.nlm.nih.gov/pubmed/31796073
http://dx.doi.org/10.1186/s13058-019-1196-y

Ejemplares similares